ClinicalTrials.gg
TerminatedNCT03869190Updated Aug 3, 2026Results posted

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

A Phase 1/2 interventional study of Atezolizumab and Enfortumab Vedotin in Urothelial Carcinoma and Bladder Cancer, sponsored by Hoffmann-La Roche. Terminated at 33 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Study was closed early as the sponsor decided not to continue development of certain treatment combinations.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
272
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing enfortumab vedotin in Carcinoma, Transitional Cell — 10 open to participants now, 15 under way, 1 of them phase 3. enfortumab vedotin · Carcinoma, Transitional Cell.

Enrollment
3rd of 20
272 · median 49
Started
2019
the only one that year
Phase 1/2
4 of 20
1 open now
Registered
4th of 20
by date
Lead sponsor
1 of 20
Hoffmann-La Roche

Among the 20 studies testing enfortumab vedotin in Carcinoma, Transitional Cell, this one is the 3rd largest by enrollment, is the only one that started in 2019, is one of 4 in phase 1/2, and was the 4th registered.

Carcinoma, Transitional Cell

632 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

10 of the 20 studies testing enfortumab vedotin in Carcinoma, Transitional Cell are open now, in 6 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About enfortumab vedotin

enfortumab vedotin: first FDA approval 2019 (PADCEV), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing enfortumab vedotin in Carcinoma, Transitional Cell, or all of them as a file.
02

Study summary

A Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with MIBC and in participants with locally advanced or metastatic Urothelial Carcinoma (UC) who have progressed during or following a platinum-containing regimen. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the participant population (e.g., with regard to prior anti-cancer treatment or biomarker status). Participants in the mUC Cohort who experience loss of clinical benefit or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment regimen for Stage 2.

03

Conditions studied

  • Urothelial Carcinoma
  • Bladder Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for mUC Cohort:

  • documented, locally advanced or UC (also termed TCC or urothelial cell carcinoma of the urinary tract; including renal pelvis, ureters, urinary bladder, and urethra)
  • Availability of a representative tumor specimen that is suitable for determination of and/or additional biomarker status by means of central testing
  • Disease progression during or following treatment with no more than one platinum-containing regimen for inoperable, locally advanced or metastatic UC or disease recurrence
  • Performance Status of 0 or 1
  • (at least one target lesion) according to v1.1
  • Adequate hematologic and end-organ function
  • Negative test at screening
  • Negative total core antibody (HBcAb) test and virus (HCV) antibody at screening
  • Tumor accessible for
  • For women of : agreement to remain abstinent or use measures and agreement to refrain from donating eggs
  • For men: agreement to remain abstinent or use contraceptive measures, and agreement to refrain from donating sperm

Inclusion Criteria for MIBC Cohorts:

  • ECOG PS of 0 or 1
  • Fit and planned-for cystectomy
  • Histologically documented MIBC (pT2-4, N0, M0), also termed TCC or urothelial cell carcinoma of the urinary bladder
  • N0 or M0 disease by CT or MRI
  • Adequate hematologic and end-organ function
  • Availability of TURBT specimen
  • Negative HIV, HBcAb, and HCV test at screening
  • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating eggs as outlined for each specific treatment arm
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as outlined for each specific treatment arm

Exclusion Criteria for mUC Cohort:

  • Prior treatment with a T-cell co-stimulating therapy or a CPI including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies
  • Prior treatment with any of the protocol-specified study treatments including treatment with poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor, nectin-4 targeting agents, signal regulatory protein alpha-targeting agents, or TIGIT-targeting agents, Trop-2 targeting agents, FAP-directed therapies, 4-1BB (CD137)-directed therapies, or topoisomerase 1 inhibitors
  • Treatment with therapy within 28 days prior to initiation of study treatment
  • Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3 weeks prior to initiation of study treatment
  • Eligibility only for the control arm
  • Prior allogeneic stem cell or solid organ transplantation
  • Treatment with systemic immunostimulatory agents within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to the initiation of study treatment
  • Treatment with systemic medication within 2 weeks prior to initiation of study treatment or anticipation of need for systemic immunosuppressant medication during study treatment
  • Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the last dose of atezolizumab
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
  • Uncontrolled tumor-related pain
  • Uncontrolled or symptomatic hypercalcemia
  • Symptomatic, untreated, or actively progressing
  • History of
  • Active or history of disease or immune deficiency
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis
  • History of other than UC within 2 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death
  • Active tuberculosis
  • Severe infection within 4 weeks prior to initiation of study treatment
  • Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment
  • Significant cardiovascular disease
  • Uncontrolled hypertension
  • Grade 3 or greater hemorrhage or bleeding event within 28 days prior to initiation of study treatment
  • Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment
  • Pregnancy or breastfeeding, or intention of becoming pregnant during the study
  • Additional drug-specific exclusion criteria might apply

Exclusion for MIBC Cohorts:

  • Prior treatment with systemic immunostimulatory agents prior to the initiation of study treatment
  • Eligibility only for the control arm
  • Prior allogeneic stem cell or solid organ transplantation
  • Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressant medication during study treatment, with the following exceptions: Patients who received acute, low-dose, systemic immunosuppressant medications, or a one-time pulse dose of systemic immunosuppressant medication are eligible for the study after Medical Monitor approval has been obtained. Patients who received mineralocorticoids, for or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.
  • Severe infection within 4 weeks prior to initiation of study treatment
  • Pregnancy or breastfeeding, or intention of becoming pregnant during the study
  • Also includes all the mUC exclusion criteria

Additional Exclusion Criteria for Atezo+Tira and Atezo (Atezolizumab) +Tira+Cis (Cisplatin)+Gem (Gemcitabine) in the MIBC Cohorts:

- Active Epstein-Barr virus (EBV) infection or known or suspected chronic active EBV infection at screening.

Additional Exclusion Criteria for the Cisplatin-Eligible MIBC Cohort:

  • Patients who decline cisplatin-based chemotherapy or in whom neoadjuvant cisplatin-based therapy is not appropriate.
  • Impaired renal function.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
272 participants (actual)

Study arms

  • Active comparator
    Atezolizumab for mUC Cohort (Stage 1)

    Participants will receive atezolizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.

    Drug: Atezolizumab

  • Experimental
    Atezolizumab + Enfortumab Vedotin for mUC Cohort (Stage 1)

    Participants will receive atezolizumab and Enfortumab Vedotin (EV) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.

    Drug: Atezolizumab · Drug: Enfortumab Vedotin

  • Experimental
    Atezolizumab + Niraparib for mUC Cohort (Stage 1)

    Participants will receive atezolizumab and Niraparib (Nira) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.

    Drug: Atezolizumab · Drug: Niraparib

  • Experimental
    Atezolizumab + Magrolimab for mUC Cohort (Stage 1)

    Participants will receive atezolizumab and magrolimab (Hu5F9-G4) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.

    Drug: Atezolizumab · Drug: Magrolimab (Hu5F9-G4)

  • Experimental
    Atezolizumab + Tiragolumab for mUC Cohort (Stage 1)

    Participants will receive atezolizumab and Tiragolumab (Tira) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.

    Drug: Atezolizumab · Drug: Tiragolumab

  • Experimental
    Atezolizumab + Sacituzumab Govitecan for mUC Cohort (Stage 1)

    Participants will receive atezolizumab and Sacituzumab Govitecan (SG) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.

    Drug: Atezolizumab · Drug: Sacituzumab Govitecan

  • Experimental
    Atezolizumab + Tocilizumab for mUC Cohort (Stage 1)

    Participants will receive atezolizumab and Tocilizumab (TCZ) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.

    Drug: Atezolizumab · Drug: Tocilizumab

  • Experimental
    Atezolizumab + RO7122290 for mUC Cohort (Stage 1)

    Participants will receive atezolizumab and RO7122290 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.

    Drug: Atezolizumab

  • Experimental
    Atezolizumab + Enfortumab Vedotin for mUC Cohort (Stage 2)

    Participants will receive atezolizumab and Enfortumab Vedotin (EV) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.

    Drug: Atezolizumab · Drug: Enfortumab Vedotin

  • Experimental
    Atezolizumab + Sacituzumab Govitecan for mUC Cohort (Stage 2)

    Participants will receive atezolizumab and Sacituzumab Govitecan (SG) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.

    Drug: Atezolizumab · Drug: Sacituzumab Govitecan

  • Active comparator
    Atezolizumab for Cisplatin-ineligible MIBC Cohort 1 PD-L1+ Arm 1

    Participants will receive Atezolizumab for 3 cycles pre-surgery and 14 cycles post-surgery.

    Drug: Atezolizumab

  • Experimental
    Atezolizumab + Tiragolumab for Cisplatin-ineligible MIBC Cohort 1 PD-L1+ Arm 2

    Participants will receive Atezolizumab and Tiragolumab (Tira) for 3 cycles pre-surgery and 14 cycles post-surgery.

    Drug: Atezolizumab · Drug: Tiragolumab

  • Active comparator
    Atezolizumab for Cisplatin-ineligible MIBC Cohort 2 PD-L1- Arm 1

    Participants will receive Atezolizumab for 3 cycles pre-surgery and 14 cycles post-surgery.

    Drug: Atezolizumab

  • Experimental
    Atezolizumab + Tiragolumab for Cisplatin-ineligible MIBC Cohort 2 PD-L1- Arm 2

    Participants will receive Atezolizumab and Tiragolumab (Tira) for 3 cycles pre-surgery and 14 cycles post-surgery.

    Drug: Atezolizumab · Drug: Tiragolumab

  • Active comparator
    Cisplatin-eligible MIBC Cohort 3 Arm 1

    Participants will receive 3 cycles of Atezolizumab, Cisplatin, and Gemcitabine pre-surgery and 14 cycles of Atezolizumab only post-surgery.

    Drug: Atezolizumab · Drug: Cisplatin · Drug: Gemcitabine

  • Experimental
    Cisplatin-eligible MIBC Cohort 3 Arm 2

    Participants will receive Atezolizumab, Tiragolumab (Tira), Cisplatin and Gemcitabine for 3 cycles pre-surgery and 14 cycles of Atezolizumab and Tiragolumab (Tira) post-surgery.

    Drug: Atezolizumab · Drug: Tiragolumab · Drug: Cisplatin · Drug: Gemcitabine

Interventions

  • For the control, + EV, + Nira, + Tira, and + SG arms, + RO7122290, Atezolizumab will be administered intravenously (IV) at a fixed dose of 1200 mg every 3 weeks (Q3W) on Day 1 of each 21-day cycle. For the Atezo + Hu5F9-G4 and + TCZ arms, Atezo will be administered IV at a fixed dose of 840 mg every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle.

  • Enfortumab vedotin will be administered at a dose of 1.25 mg/kg IV on Days 1 and 8 of each 21-day cycle.

  • Niraparib will be administered at a dose of 200 mg once daily (QD) by mouth.

  • Participants will receive an 1-mg/kg priming dose IV on Day 1 followed by three weekly IV doses of 30 mg/kg on Days 8, 15, and 22. During Cycle 2, participants will receive weekly IV doses of 30 mg/kg on Days 1, 8, 15, and 22. For all subsequent cycles, participants will receive 30 mg/kg on Days 1 and 15. Cycle = 28 days.

  • Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21-day cycle.

  • Sacituzumab Govitecan will be administered at a dose of 10 mg/kg by IV on Day 1 and 8 of each 21-day cycle.

  • Tocilizumab will be administered by IV infusion at a dose of 8 mg/kg every 4 weeks (Q4W) on Day 1 of each 28-day cycle.

  • Cisplatin will be administered at a dose of 70mg/m\^2 by IV on Day 1 of each cycle for Cycles 1-3 pre-surgery.

  • Gemcitabine will be administered at a dose of 1000mg/m\^2 by IV on Days 1 and 8 of each cycle for Cycles 1-3 pre-surgery.

06

What researchers measure

Primary outcomes

  1. Stage 1 mUC Cohorts: Objective Response Rate (ORR)

    ORR was defined as the percentage of participants with an objective response (OR), characterized by a complete response (CR) or a partial response (PR), on 2 consecutive occasions ≥ 4 weeks apart during Stage 1, as determined by the investigator per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1). CR was defined as the disappearance of all target and non-target lesions and normalization of tumor marker level. Additionally, any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters (SOD) of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.

    Time frame: Up to 61.5 months

  2. MIBC Cohorts: Pathological Complete Response (pCR)

    pCR was defined as the percentage of participants with an absence of residual invasive cancer of the complete resected specimen. Percentages have been rounded off.

    Time frame: Up to 17.8 months

Secondary outcomes

  1. Stage 1 mUC Cohorts: Progression-free Survival (PFS) After Randomization

    PFS after randomization was defined as the time from randomization to the first occurrence of disease progression (PD) or death from any cause, whichever occurred first in Stage 1, as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. PFS for participants with no documented PD or death was censored at the day of the last tumor assessment. Kaplan-Meier (K-M) method was used to estimate the median PFS.

    Time frame: From randomization to PD or death from any cause, whichever occurred first (up to 62 months)

  2. Stage 1 mUC Cohorts: Overall Survival (OS) After Randomization

    OS after randomization was defined as the time from randomization to death from any cause. Data for participants who had not died were censored at the last date they were known to be alive. K-M method was used to estimate the median OS.

    Time frame: From randomization to death from any cause (up to 69.1 months)

  3. Stage 1 mUC Cohorts: OS Rate at Month 12

    OS rate at Month 12 was defined as percentage of participants who did not experience death from any cause at the specified timepoint. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate OS rate. Percentages have been rounded off.

    Time frame: At Month 12

  4. Stage 1 mUC Cohorts: Duration of Response (DOR)

    DOR was defined as the time from the first occurrence of a documented OR (CR or PR) during Stage 1 to PD or death from any cause during Stage 1, whichever occurred first, as determined by the investigator according to RECIST v1.1. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median DOR.

    Time frame: From first occurrence of a documented OR to PD or death from any cause, whichever occurred first (up to 61.5 months)

  5. Stage 1 mUC Cohorts: Disease Control Rate (DCR)

    DCR was defined as percentage of participants with stable disease for ≥ 18 weeks or an OR (CR or PR) during Stage 1, as determined by the investigator according to RECIST v1.1. SD was defined as neither sufficient shrinkage of target lesions to qualify for CR or PR nor sufficient increase to qualify for PD. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. Percentages have been rounded off.

    Time frame: Up to 61.5 months

  6. Stages 1 and 2 mUC Cohorts: Number of Participants With Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: Stage 1: Up to 62.1 months; Stage 2: Up to 18.3 months

  7. Stage 2 mUC [Atezo + EV Cohort]: Serum Concentration of Atezolizumab at Specified Timepoints

    Time frame: Predose: Day 1 of Cycles 1, 2 and 4; 30 minutes postdose: Day 1 Cycle 1

  8. Stage 2 mUC [Atezo + EV Cohort]: Number of Participants With Anti-drug Antibodies (ADAs) to Atezolizumab

    Participants were considered to be treatment-emergent ADA positive if they were ADA negative or had missing data at baseline but developed an ADA response following atezolizumab exposure (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer unit (t.u.) greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

    Time frame: Up to approximately 18.3 months

  9. MIBC Cohorts: Landmark Recurrence-free Survival (RFS) Rate

    Landmark RFS was defined as the percentage of participants who were alive without disease recurrence at specified timepoints following surgery. RFS was defined as the time from Day 1 in the first cycle after surgery to the first documented recurrence of disease or death from any cause. RFS rates at the specified landmark timepoints were estimated using the K-M method.

    Time frame: At Months 12, 18, and 24

  10. MIBC Cohorts: Landmark Event-free Survival (EFS) Rate

    Landmark EFS was defined as the percentage of participants who were alive without experiencing a predefined event at specified timepoints. EFS was defined as the time from randomization to any of the following events, whichever occurred first: PD that precludes surgery, as assessed by the investigator; local or distant disease recurrence; or death from any cause. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. EFS rates at the specified landmark timepoints were estimated using the K-M method.

    Time frame: At Months 12, 18, and 24

  11. MIBC Cohorts: Landmark OS Rate

    Landmark OS was defined as the percentage of participants who were alive at specified timepoints. OS was defined as the time from randomization to death from any cause. OS rates at the specified landmark timepoints were estimated using the K-M method.

    Time frame: At Months 12, 18, and 24

  12. MIBC Cohorts: Number of Participants With AEs

    An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: Up to 17.8 months

07

Results

Posted Aug 3, 2026

Participant flow

A total of 272 participants with muscle-invasive bladder cancer (MIBC) or locally advanced or metastatic urothelial carcinoma (mUC) who had progressed during or following a platinum-containing regimen took part in the study across 7 countries from 01 June 2019 to 22 December 2025.

Stage 1
Participant flow — Stage 1
MilestoneStage 1 mUC Cohort: Atezo (Control)Stage 1 mUC Cohort: Atezo + EVStage 1 mUC Cohort: Atezo + Hu5F9-G4Stage 1 mUC Cohort: Atezo + NiraStage 1 mUC Cohort: Atezo + RO7122290Stage 1 mUC Cohort: Atezo + SGStage 1 mUC Cohort: Atezo + TiraStage 1 mUC Cohort: Atezo + TCZStage 1 MIBC Cohort 1: Atezo (Control)Stage 1 MIBC Cohort 1: Atezo + TiraStage 1 MIBC Cohort 2: Atezo (Control)Stage 1 MIBC Cohort 2: Atezo + TiraStage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control)Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + TiraStage 2 mUC Cohort: Atezo + EVStage 2 mUC Cohort: Atezo + SG
Started30151615121531156112347181800
Safety-evaluable (se) population29151515121530156112346181700
Completed2812151311132715592041161500
Not completed2312124012362300
Withdrew: Death1301012001142100
Withdrew: Withdrawal by subject1011111011210100
Withdrew: Study terminated by sponsor0000001000000000
Withdrew: Sponsor decision0000000000000100
Withdrew: Reason not specified0000000000010000
Stage 2
Participant flow — Stage 2
MilestoneStage 1 mUC Cohort: Atezo (Control)Stage 1 mUC Cohort: Atezo + EVStage 1 mUC Cohort: Atezo + Hu5F9-G4Stage 1 mUC Cohort: Atezo + NiraStage 1 mUC Cohort: Atezo + RO7122290Stage 1 mUC Cohort: Atezo + SGStage 1 mUC Cohort: Atezo + TiraStage 1 mUC Cohort: Atezo + TCZStage 1 MIBC Cohort 1: Atezo (Control)Stage 1 MIBC Cohort 1: Atezo + TiraStage 1 MIBC Cohort 2: Atezo (Control)Stage 1 MIBC Cohort 2: Atezo + TiraStage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control)Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + TiraStage 2 mUC Cohort: Atezo + EVStage 2 mUC Cohort: Atezo + SG
Started000000000000001515
Se population000000000000001515
Completed000000000000001511
Not completed0000000000000004
Withdrew: Death0000000000000003
Withdrew: Withdrawal by subject0000000000000001
Long-term Survival Follow-up (LTSFU)
Participant flow — Long-term Survival Follow-up (LTSFU)
MilestoneStage 1 mUC Cohort: Atezo (Control)Stage 1 mUC Cohort: Atezo + EVStage 1 mUC Cohort: Atezo + Hu5F9-G4Stage 1 mUC Cohort: Atezo + NiraStage 1 mUC Cohort: Atezo + RO7122290Stage 1 mUC Cohort: Atezo + SGStage 1 mUC Cohort: Atezo + TiraStage 1 mUC Cohort: Atezo + TCZStage 1 MIBC Cohort 1: Atezo (Control)Stage 1 MIBC Cohort 1: Atezo + TiraStage 1 MIBC Cohort 2: Atezo (Control)Stage 1 MIBC Cohort 2: Atezo + TiraStage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control)Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + TiraStage 2 mUC Cohort: Atezo + EVStage 2 mUC Cohort: Atezo + SG
Started1711138913211159204116151511
Completed0000000003375500
Not completed1711138913211156173411101511
Withdrew: Reason not specified1000000000040001
Withdrew: Death1210867816101171331119
Withdrew: Arm terminated by sponsor0131230100001031
Withdrew: Withdrawal by subject0021000001270000
Withdrew: Study terminated by sponsor20000050448107900
Withdrew: Physician decision2000010000000010
Withdrew: Lost to follow-up0000010000000000

Outcome measures

SecondaryStage 1 mUC Cohorts: Progression-free Survival (PFS) After Randomization

PFS after randomization was defined as the time from randomization to the first occurrence of disease progression (PD) or death from any cause, whichever occurred first in Stage 1, as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. PFS for participants with no documented PD or death was censored at the day of the last tumor assessment. Kaplan-Meier (K-M) method was used to estimate the median PFS.

Time frame:
From randomization to PD or death from any cause, whichever occurred first (up to 62 months)
Reported as:
Median · months
Stage 1 mUC Cohorts: Progression-free Survival (PFS) After Randomization
monthsStage 1 mUC Cohort: Atezo (Control)Stage 1 mUC Cohort: Atezo + EVStage 1 mUC Cohort: Atezo + Hu5F9-G4Stage 1 mUC Cohort: Atezo + NiraStage 1 mUC Cohort: Atezo + RO7122290Stage 1 mUC Cohort: Atezo + SGStage 1 mUC Cohort: Atezo + TiraStage 1 mUC Cohort: Atezo + TCZ
Stage 1 mUC Cohorts: Progression-free Survival (PFS) After Randomization6.05 (3.52 to 10.18)4.47 (3.45 to 6.24)2.32 (1.97 to 10.51)2.23 (2.00 to 2.99)3.06 (2.10 to 14.32)3.48 (2.14 to 8.28)3.14 (2.10 to 4.86)4.07 (2.27 to 8.34)
Statistical analysis
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + EV · Hazard ratio (hr): 1.39 · 95% CI 0.72 to 2.69
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + Hu5F9-G4 · Hazard ratio (hr): 1.16 · 95% CI 0.57 to 2.34
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + Nira · Hazard ratio (hr): 2.16 · 95% CI 1.06 to 4.42
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + RO7122290 · Hazard ratio (hr): 1.16 · 95% CI 0.54 to 2.53
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + SG · Hazard ratio (hr): 1.27 · 95% CI 0.64 to 2.54
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + Tira · Hazard ratio (hr): 1.24 · 95% CI 0.72 to 2.16
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + TCZ · Hazard ratio (hr): 1.31 · 95% CI 0.67 to 2.55
SecondaryStage 1 mUC Cohorts: Overall Survival (OS) After Randomization

OS after randomization was defined as the time from randomization to death from any cause. Data for participants who had not died were censored at the last date they were known to be alive. K-M method was used to estimate the median OS.

Time frame:
From randomization to death from any cause (up to 69.1 months)
Reported as:
Median · months
Stage 1 mUC Cohorts: Overall Survival (OS) After Randomization
monthsStage 1 mUC Cohort: Atezo (Control)Stage 1 mUC Cohort: Atezo + EVStage 1 mUC Cohort: Atezo + Hu5F9-G4Stage 1 mUC Cohort: Atezo + NiraStage 1 mUC Cohort: Atezo + RO7122290Stage 1 mUC Cohort: Atezo + SGStage 1 mUC Cohort: Atezo + TiraStage 1 mUC Cohort: Atezo + TCZ
Stage 1 mUC Cohorts: Overall Survival (OS) After Randomization18.79 (10.64 to 31.54)6.83 (5.62 to 10.68)21.82 (7.20 to NA)8.57 (5.16 to 35.45)7.33 (4.34 to 16.66)14.55 (8.25 to NA)12.32 (4.40 to 34.86)6.28 (5.13 to 19.88)
Statistical analysis
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + EV · Hazard ratio (hr): 2.52 · 95% CI 1.23 to 5.17
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + Hu5F9-G4 · Hazard ratio (hr): 1.01 · 95% CI 0.46 to 2.24
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + Nira · Hazard ratio (hr): 1.50 · 95% CI 0.71 to 3.16
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + RO7122290 · Hazard ratio (hr): 1.83 · 95% CI 0.82 to 4.11
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + SG · Hazard ratio (hr): 1.15 · 95% CI 0.51 to 2.58
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + Tira · Hazard ratio (hr): 1.14 · 95% CI 0.63 to 2.08
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + TCZ · Hazard ratio (hr): 1.74 · 95% CI 0.85 to 3.53
SecondaryStage 1 mUC Cohorts: OS Rate at Month 12

OS rate at Month 12 was defined as percentage of participants who did not experience death from any cause at the specified timepoint. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate OS rate. Percentages have been rounded off.

Time frame:
At Month 12
Reported as:
Number · percentage of participants
Stage 1 mUC Cohorts: OS Rate at Month 12
percentage of participantsStage 1 mUC Cohort: Atezo (Control)Stage 1 mUC Cohort: Atezo + EVStage 1 mUC Cohort: Atezo + Hu5F9-G4Stage 1 mUC Cohort: Atezo + NiraStage 1 mUC Cohort: Atezo + RO7122290Stage 1 mUC Cohort: Atezo + SGStage 1 mUC Cohort: Atezo + TiraStage 1 mUC Cohort: Atezo + TCZ
Stage 1 mUC Cohorts: OS Rate at Month 1264.77 (47.15 to 82.39)26.67 (4.29 to 49.05)61.90 (35.56 to 88.25)39.16 (12.54 to 65.78)36.36 (7.94 to 64.79)61.90 (35.56 to 88.25)52.94 (34.95 to 70.93)40.00 (15.21 to 64.79)
Statistical analysis
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + EV · Difference in event-free rate: -38.10 · 95% CI -66.58 to -9.62
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + Hu5F9-G4 · Difference in event-free rate: -2.86 · 95% CI -34.56 to 28.83
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + Nira · Difference in event-free rate: -25.61 · 95% CI -57.53 to 6.31
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + RO7122290 · Difference in event-free rate: -28.40 · 95% CI -61.85 to 5.04
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + SG · Difference in event-free rate: -2.86 · 95% CI -34.56 to 28.83
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + Tira · Difference in event-free rate: -11.83 · 95% CI -37.01 to 13.35
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + TCZ · Difference in event-free rate: -24.77 · 95% CI -55.18 to 5.65
SecondaryStage 1 mUC Cohorts: Duration of Response (DOR)

DOR was defined as the time from the first occurrence of a documented OR (CR or PR) during Stage 1 to PD or death from any cause during Stage 1, whichever occurred first, as determined by the investigator according to RECIST v1.1. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median DOR.

Time frame:
From first occurrence of a documented OR to PD or death from any cause, whichever occurred first (up to 61.5 months)
Reported as:
Median · months
Stage 1 mUC Cohorts: Duration of Response (DOR)
monthsStage 1 mUC Cohort: Atezo (Control)Stage 1 mUC Cohort: Atezo + EVStage 1 mUC Cohort: Atezo + Hu5F9-G4Stage 1 mUC Cohort: Atezo + NiraStage 1 mUC Cohort: Atezo + RO7122290Stage 1 mUC Cohort: Atezo + SGStage 1 mUC Cohort: Atezo + TiraStage 1 mUC Cohort: Atezo + TCZ
Stage 1 mUC Cohorts: Duration of Response (DOR)32.16 (6.24 to NA)8.66 (4.07 to NA)NA (8.34 to NA)13.11 (NA to NA)NA (NA to NA)21.42 (NA to NA)42.74 (21.62 to NA)11.43 (6.24 to NA)
Statistical analysis
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + EV · Hazard ratio (hr): 2.76 · 95% CI 0.68 to 11.13
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + Hu5F9-G4 · Hazard ratio (hr): 0.78 · 95% CI 0.14 to 4.27
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + Nira · Hazard ratio (hr): 1.43 · 95% CI 0.16 to 12.94
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + SG · Hazard ratio (hr): 1.43 · 95% CI 0.16 to 12.94
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + Tira · Hazard ratio (hr): 0.59 · 95% CI 0.14 to 2.47
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + TCZ · Hazard ratio (hr): 1.23 · 95% CI 0.22 to 7.00
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + RO7122290 · Hazard ratio (hr): 0.009
SecondaryStage 1 mUC Cohorts: Disease Control Rate (DCR)

DCR was defined as percentage of participants with stable disease for ≥ 18 weeks or an OR (CR or PR) during Stage 1, as determined by the investigator according to RECIST v1.1. SD was defined as neither sufficient shrinkage of target lesions to qualify for CR or PR nor sufficient increase to qualify for PD. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. Percentages have been rounded off.

Time frame:
Up to 61.5 months
Reported as:
Number · percentage of participants
Stage 1 mUC Cohorts: Disease Control Rate (DCR)
percentage of participantsStage 1 mUC Cohort: Atezo (Control)Stage 1 mUC Cohort: Atezo + EVStage 1 mUC Cohort: Atezo + Hu5F9-G4Stage 1 mUC Cohort: Atezo + NiraStage 1 mUC Cohort: Atezo + RO7122290Stage 1 mUC Cohort: Atezo + SGStage 1 mUC Cohort: Atezo + TiraStage 1 mUC Cohort: Atezo + TCZ
Stage 1 mUC Cohorts: Disease Control Rate (DCR)48.3 (29.45 to 67.47)40.0 (16.34 to 67.71)26.7 (7.79 to 55.10)13.3 (1.66 to 40.46)25.0 (5.49 to 57.19)33.3 (11.82 to 61.62)30.0 (14.73 to 49.40)26.7 (7.79 to 55.10)
SecondaryStages 1 and 2 mUC Cohorts: Number of Participants With Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
Stage 1: Up to 62.1 months; Stage 2: Up to 18.3 months
Reported as:
Count of participants · Participants
Stages 1 and 2 mUC Cohorts: Number of Participants With Adverse Events (AEs)
ParticipantsStage 1 mUC Cohort: Atezo (Control)Stage 1 mUC Cohort: Atezo + EVStage 1 mUC Cohort: Atezo + Hu5F9-G4Stage 1 mUC Cohort: Atezo + NiraStage 1 mUC Cohort: Atezo + RO7122290Stage 1 mUC Cohort: Atezo + SGStage 1 mUC Cohort: Atezo + TiraStage 1 mUC Cohort: Atezo + TCZStage 2 mUC Cohort: Atezo + EVStage 2 mUC Cohort: Atezo + SG
Stages 1 and 2 mUC Cohorts: Number of Participants With Adverse Events (AEs)29151415121530141515
SecondaryStage 2 mUC [Atezo + EV Cohort]: Serum Concentration of Atezolizumab at Specified Timepoints
Time frame:
Predose: Day 1 of Cycles 1, 2 and 4; 30 minutes postdose: Day 1 Cycle 1
Reported as:
Geometric mean · micrograms per milliliter (µg/mL)
Stage 2 mUC [Atezo + EV Cohort]: Serum Concentration of Atezolizumab at Specified Timepoints
micrograms per milliliter (µg/mL)Stage 2 mUC Cohort: Atezo + EV
Predose: Cycle 1 Day 1107 ± 60.1
30 min Postdose: Cycle 1 Day 1390 ± 25.3
Predose: Cycle 2 Day 1105 ± 57.1
Predose: Cycle 4 Day 1121 ± 43.4
SecondaryStage 2 mUC [Atezo + EV Cohort]: Number of Participants With Anti-drug Antibodies (ADAs) to Atezolizumab

Participants were considered to be treatment-emergent ADA positive if they were ADA negative or had missing data at baseline but developed an ADA response following atezolizumab exposure (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer unit (t.u.) greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

Time frame:
Up to approximately 18.3 months
Reported as:
Count of participants · Participants
Stage 2 mUC [Atezo + EV Cohort]: Number of Participants With Anti-drug Antibodies (ADAs) to Atezolizumab
ParticipantsStage 2 mUC Cohort: Atezo + EV
Stage 2 mUC [Atezo + EV Cohort]: Number of Participants With Anti-drug Antibodies (ADAs) to Atezolizumab5
SecondaryMIBC Cohorts: Landmark Recurrence-free Survival (RFS) Rate

Landmark RFS was defined as the percentage of participants who were alive without disease recurrence at specified timepoints following surgery. RFS was defined as the time from Day 1 in the first cycle after surgery to the first documented recurrence of disease or death from any cause. RFS rates at the specified landmark timepoints were estimated using the K-M method.

Time frame:
At Months 12, 18, and 24
Reported as:
Number · percentage of participants
MIBC Cohorts: Landmark Recurrence-free Survival (RFS) Rate
percentage of participantsStage 1 MIBC Cohort 1: Atezo (Control)Stage 1 MIBC Cohort 1: Atezo + TiraStage 1 MIBC Cohort 2: Atezo (Control)Stage 1 MIBC Cohort 2: Atezo + TiraStage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control)Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira
Month 12100.00 (100.00 to 100.00)66.67 (28.95 to 100.00)81.82 (59.03 to 100.00)68.00 (49.71 to 86.29)80.00 (55.21 to 100.00)100.00 (100.00 to 100.00)
Month 18NA (NA to NA)66.67 (28.95 to 100.00)68.18 (37.26 to 99.10)63.47 (44.36 to 82.57)80.00 (55.21 to 100.00)91.67 (76.03 to 100.00)
Month 24NA (NA to NA)66.67 (28.95 to 100.00)68.18 (37.26 to 99.10)57.70 (37.26 to 78.14)70.00 (41.60 to 98.40)81.48 (58.08 to 100.00)
Statistical analysis
  • Stage 1 MIBC Cohort 1: Atezo (Control) vs Stage 1 MIBC Cohort 1: Atezo + Tira · Difference in event-free rate: -33.33 · 95% CI -71.05 to 4.39
  • Stage 1 MIBC Cohort 2: Atezo (Control) vs Stage 1 MIBC Cohort 2: Atezo + Tira · Difference in event-free rate: -13.82 · 95% CI -43.04 to 15.40
  • Stage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control) vs Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira · Difference in event-free rate: 20.00 · 95% CI -4.79 to 44.79
  • Stage 1 MIBC Cohort 2: Atezo (Control) vs Stage 1 MIBC Cohort 2: Atezo + Tira · Difference in event-free rate: -4.72 · 95% CI -41.06 to 31.63
  • Stage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control) vs Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira · Difference in event-free rate: 11.67 · 95% CI -17.64 to 40.98
  • Stage 1 MIBC Cohort 2: Atezo (Control) vs Stage 1 MIBC Cohort 2: Atezo + Tira · Difference in event-free rate: -10.48 · 95% CI -47.55 to 26.58
  • Stage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control) vs Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira · Difference in event-free rate: 11.48 · 95% CI -25.32 to 48.28
SecondaryMIBC Cohorts: Landmark Event-free Survival (EFS) Rate

Landmark EFS was defined as the percentage of participants who were alive without experiencing a predefined event at specified timepoints. EFS was defined as the time from randomization to any of the following events, whichever occurred first: PD that precludes surgery, as assessed by the investigator; local or distant disease recurrence; or death from any cause. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. EFS rates at the specified landmark timepoints were estimated using the K-M method.

Time frame:
At Months 12, 18, and 24
Reported as:
Number · percentage of participants
MIBC Cohorts: Landmark Event-free Survival (EFS) Rate
percentage of participantsStage 1 MIBC Cohort 1: Atezo (Control)Stage 1 MIBC Cohort 1: Atezo + TiraStage 1 MIBC Cohort 2: Atezo (Control)Stage 1 MIBC Cohort 2: Atezo + TiraStage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control)Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira
Month 1283.33 (53.51 to 100.00)75.00 (44.99 to 100.00)73.68 (53.88 to 93.48)61.13 (46.23 to 76.04)59.58 (36.21 to 82.96)92.86 (79.37 to 100.00)
Month 1883.33 (53.51 to 100.00)75.00 (44.99 to 100.00)60.79 (37.72 to 83.86)56.24 (41.06 to 71.42)59.58 (36.21 to 82.96)85.12 (66.05 to 100.00)
Month 2483.33 (53.51 to 100.00)75.00 (44.99 to 100.00)45.59 (20.45 to 70.73)49.32 (33.23 to 65.42)52.96 (28.85 to 77.07)85.12 (66.05 to 100.00)
Statistical analysis
  • Stage 1 MIBC Cohort 1: Atezo (Control) vs Stage 1 MIBC Cohort 1: Atezo + Tira · Difference in event-free rate: -8.33 · 95% CI -50.64 to 33.97
  • Stage 1 MIBC Cohort 2: Atezo (Control) vs Stage 1 MIBC Cohort 2: Atezo + Tira · Difference in event-free rate: -12.55 · 95% CI -37.34 to 12.23
  • Stage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control) vs Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira · Difference in event-free rate: 33.27 · 95% CI 6.29 to 60.26
  • Stage 1 MIBC Cohort 1: Atezo (Control) vs Stage 1 MIBC Cohort 1: Atezo + Tira · Difference in event-free rate: -8.33 · 95% CI -50.64 to 33.97
  • Stage 1 MIBC Cohort 2: Atezo (Control) vs Stage 1 MIBC Cohort 2: Atezo + Tira · Difference in event-free rate: -4.55 · 95% CI -32.16 to 23.07
  • Stage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control) vs Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira · Difference in event-free rate: 25.54 · 95% CI -4.63 to 55.70
  • Stage 1 MIBC Cohort 1: Atezo (Control) vs Stage 1 MIBC Cohort 1: Atezo + Tira · Difference in event-free rate: -8.33 · 95% CI -50.64 to 33.97
  • Stage 1 MIBC Cohort 2: Atezo (Control) vs Stage 1 MIBC Cohort 2: Atezo + Tira · Difference in event-free rate: 3.73 · 95% CI -26.12 to 33.58
  • Stage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control) vs Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira · Difference in event-free rate: 32.16 · 95% CI 1.41 to 62.90
SecondaryMIBC Cohorts: Landmark OS Rate

Landmark OS was defined as the percentage of participants who were alive at specified timepoints. OS was defined as the time from randomization to death from any cause. OS rates at the specified landmark timepoints were estimated using the K-M method.

Time frame:
At Months 12, 18, and 24
Reported as:
Number · percentage of participants
MIBC Cohorts: Landmark OS Rate
percentage of participantsStage 1 MIBC Cohort 1: Atezo (Control)Stage 1 MIBC Cohort 1: Atezo + TiraStage 1 MIBC Cohort 2: Atezo (Control)Stage 1 MIBC Cohort 2: Atezo + TiraStage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control)Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira
Month 1283.33 (53.51 to 100.00)88.89 (68.36 to 100.00)76.22 (57.95 to 94.50)75.01 (62.18 to 87.84)77.78 (58.57 to 96.98)93.75 (81.89 to 100.00)
Month 1883.33 (53.51 to 100.00)88.89 (68.36 to 100.00)64.88 (43.59 to 86.17)67.98 (54.10 to 81.86)72.22 (51.53 to 92.91)93.75 (81.89 to 100.00)
Month 2483.33 (53.51 to 100.00)88.89 (68.36 to 100.00)58.39 (35.75 to 81.04)61.83 (46.77 to 76.88)72.22 (51.53 to 92.91)87.50 (71.30 to 100.00)
Statistical analysis
  • Stage 1 MIBC Cohort 1: Atezo (Control) vs Stage 1 MIBC Cohort 1: Atezo + Tira · Difference in event-free rate: 5.56 · 95% CI -30.65 to 41.76
  • Stage 1 MIBC Cohort 2: Atezo (Control) vs Stage 1 MIBC Cohort 2: Atezo + Tira · Difference in event-free rate: -1.21 · 95% CI -23.54 to 21.12
  • Stage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control) vs Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira · Difference in event-free rate: 15.97 · 95% CI -6.60 to 38.55
  • Stage 1 MIBC Cohort 1: Atezo (Control) vs Stage 1 MIBC Cohort 1: Atezo + Tira · Difference in event-free rate: 5.56 · 95% CI -30.65 to 41.76
  • Stage 1 MIBC Cohort 2: Atezo (Control) vs Stage 1 MIBC Cohort 2: Atezo + Tira · Difference in event-free rate: 3.10 · 95% CI -22.32 to 28.52
  • Stage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control) vs Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira · Difference in event-free rate: 21.53 · 95% CI -2.32 to 45.38
  • Stage 1 MIBC Cohort 1: Atezo (Control) vs Stage 1 MIBC Cohort 1: Atezo + Tira · Difference in event-free rate: 5.56 · 95% CI -30.65 to 41.76
  • Stage 1 MIBC Cohort 2: Atezo (Control) vs Stage 1 MIBC Cohort 2: Atezo + Tira · Difference in event-free rate: 3.43 · 95% CI -23.76 to 30.63
  • Stage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control) vs Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira · Difference in event-free rate: 15.28 · 95% CI -11.00 to 41.56
SecondaryMIBC Cohorts: Number of Participants With AEs

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
Up to 17.8 months
Reported as:
Count of participants · Participants
MIBC Cohorts: Number of Participants With AEs
ParticipantsStage 1 MIBC Cohort 1: Atezo (Control)Stage 1 MIBC Cohort 1: Atezo + TiraStage 1 MIBC Cohort 2: Atezo (Control)Stage 1 MIBC Cohort 2: Atezo + TiraStage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control)Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira
MIBC Cohorts: Number of Participants With AEs61123451817
PrimaryStage 1 mUC Cohorts: Objective Response Rate (ORR)

ORR was defined as the percentage of participants with an objective response (OR), characterized by a complete response (CR) or a partial response (PR), on 2 consecutive occasions ≥ 4 weeks apart during Stage 1, as determined by the investigator per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1). CR was defined as the disappearance of all target and non-target lesions and normalization of tumor marker level. Additionally, any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters (SOD) of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.

Time frame:
Up to 61.5 months
Reported as:
Number · percentage of participants
Stage 1 mUC Cohorts: Objective Response Rate (ORR)
percentage of participantsStage 1 mUC Cohort: Atezo (Control)Stage 1 mUC Cohort: Atezo + EVStage 1 mUC Cohort: Atezo + Hu5F9-G4Stage 1 mUC Cohort: Atezo + NiraStage 1 mUC Cohort: Atezo + RO7122290Stage 1 mUC Cohort: Atezo + SGStage 1 mUC Cohort: Atezo + TiraStage 1 mUC Cohort: Atezo + TCZ
Stage 1 mUC Cohorts: Objective Response Rate (ORR)27.6 (12.73 to 47.24)26.7 (7.79 to 55.10)26.7 (7.79 to 55.10)6.7 (0.17 to 31.95)16.7 (2.09 to 48.41)6.7 (0.17 to 31.95)20.0 (7.71 to 38.57)20.0 (4.33 to 48.09)
Statistical analysis
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + EV · Difference in overall response rates: -0.92 · 95% CI -33.64 to 31.80
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + Hu5F9-G4 · Difference in overall response rates: -0.92 · 95% CI -33.64 to 31.80
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + Nira · Difference in overall response rates: -20.92 · 95% CI -46.57 to 4.73
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + RO7122290 · Difference in overall response rates: -10.92 · 95% CI -43.44 to 21.60
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + SG · Difference in overall response rates: -20.92 · 95% CI -46.57 to 4.73
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + Tira · Difference in overall response rates: -7.59 · 95% CI -32.64 to 17.47
  • Stage 1 mUC Cohort: Atezo (Control) vs Stage 1 mUC Cohort: Atezo + TCZ · Difference in overall response rates: -7.59 · 95% CI -38.61 to 23.44
PrimaryMIBC Cohorts: Pathological Complete Response (pCR)

pCR was defined as the percentage of participants with an absence of residual invasive cancer of the complete resected specimen. Percentages have been rounded off.

Time frame:
Up to 17.8 months
Reported as:
Number · percentage of participants
MIBC Cohorts: Pathological Complete Response (pCR)
percentage of participantsStage 1 MIBC Cohort 1: Atezo (Control)Stage 1 MIBC Cohort 1: Atezo + TiraStage 1 MIBC Cohort 2: Atezo (Control)Stage 1 MIBC Cohort 2: Atezo + TiraStage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control)Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira
MIBC Cohorts: Pathological Complete Response (pCR)66.7 (22.28 to 95.67)27.3 (6.02 to 60.97)21.7 (7.46 to 43.70)20.0 (9.58 to 34.60)27.8 (9.69 to 53.48)23.5 (6.81 to 49.90)
Statistical analysis
  • Stage 1 MIBC Cohort 1: Atezo (Control) vs Stage 1 MIBC Cohort 1: Atezo + Tira · Difference in pcr rates: -39.39 · 95% CI -98.27 to 19.48
  • Stage 1 MIBC Cohort 2: Atezo (Control) vs Stage 1 MIBC Cohort 2: Atezo + Tira · Difference in pcr rates: -1.74 · 95% CI -25.54 to 22.06
  • Stage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control) vs Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira · Difference in pcr rates: -4.25 · 95% CI -38.86 to 30.36

Adverse events

Collected over All AEs: Stage 1 mUC cohorts: Up to 62.1 months; Stage 2 mUC cohorts: Up to 18.3 months; MIBC cohorts: Up to 17.8 months All-cause mortality: Stage 1 & Stage 2 mUC cohorts: Up to 69.1 months; MIBC cohorts: Up to 42.2 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Stage 1 mUC Cohort: Atezo (Control)13/30 (43.3%)11/29 (37.9%)29/29 (100%)
Stage 1 mUC Cohort: Atezo + EV13/15 (86.7%)9/15 (60%)14/15 (93.3%)
Stage 1 mUC Cohort: Atezo + Hu5F9-G48/16 (50%)8/15 (53.3%)14/15 (93.3%)
Stage 1 mUC Cohort: Atezo + Nira8/15 (53.3%)7/15 (46.7%)15/15 (100%)
Stage 1 mUC Cohort: Atezo + RO71222907/12 (58.3%)9/12 (75%)11/12 (91.7%)
Stage 1 Cohort 1 mUC Atezo+SG9/15 (60%)9/15 (60%)14/15 (93.3%)
Stage 1 mUC Cohort: Atezo + Tira19/31 (61.3%)12/30 (40%)30/30 (100%)
Stage 1 mUC Cohort: Atezo + TCZ10/15 (66.7%)8/15 (53.3%)14/15 (93.3%)
Stage 1 MIBC Cohort 1: Atezo (Control)1/6 (16.7%)5/6 (83.3%)6/6 (100%)
Stage 1 MIBC Cohort 1: Atezo + Tira2/11 (18.2%)6/11 (54.5%)11/11 (100%)
Stage 1 MIBC Cohort 2: Atezo (Control)8/23 (34.8%)14/23 (60.9%)22/23 (95.7%)
Stage 1 MIBC Cohort 2: Atezo + Tira17/47 (36.2%)35/46 (76.1%)41/46 (89.1%)
Stage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control)5/18 (27.8%)10/18 (55.6%)18/18 (100%)
Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira2/18 (11.1%)10/17 (58.8%)16/17 (94.1%)
Stage 2 mUC Cohort: Atezo + EV11/15 (73.3%)8/15 (53.3%)15/15 (100%)
Stage 2 mUC Cohort: Atezo + SG12/15 (80%)10/15 (66.7%)15/15 (100%)
Most frequent serious events
Showing 10 of 155
Most frequent serious events
EventStage 1 mUC Cohort: Atezo (Control)Stage 1 mUC Cohort: Atezo + EVStage 1 mUC Cohort: Atezo + Hu5F9-G4Stage 1 mUC Cohort: Atezo + NiraStage 1 mUC Cohort: Atezo + RO7122290Stage 1 Cohort 1 mUC Atezo+SGStage 1 mUC Cohort: Atezo + TiraStage 1 mUC Cohort: Atezo + TCZStage 1 MIBC Cohort 1: Atezo (Control)Stage 1 MIBC Cohort 1: Atezo + TiraStage 1 MIBC Cohort 2: Atezo (Control)Stage 1 MIBC Cohort 2: Atezo + TiraStage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control)Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + TiraStage 2 mUC Cohort: Atezo + EVStage 2 mUC Cohort: Atezo + SG
Urinary tract infectionInfections and infestations2/291/151/150/150/121/151/301/151/64/114/238/461/186/172/151/15
Acute kidney injuryRenal and urinary disorders0/290/150/151/150/121/150/301/152/60/111/239/461/181/170/151/15
SepsisInfections and infestations0/290/151/151/150/122/150/300/150/63/113/234/462/180/171/153/15
PyrexiaGeneral disorders1/292/151/150/150/120/152/300/150/60/110/231/460/182/170/153/15
Acute coronary syndromeCardiac disorders0/290/150/150/150/120/150/300/151/60/110/230/460/180/170/150/15
Enterovesical fistulaGastrointestinal disorders0/290/150/150/150/120/150/300/151/60/110/230/460/180/170/150/15
EpilepsyNervous system disorders0/290/150/150/150/120/150/300/151/60/110/230/460/180/170/150/15
Urinary retentionRenal and urinary disorders0/290/150/150/150/120/150/300/151/60/110/230/460/180/170/150/15
PneumonitisRespiratory, thoracic and mediastinal disorders0/291/150/150/152/120/150/301/150/60/110/230/460/180/171/150/15
Febrile neutropeniaBlood and lymphatic system disorders0/290/150/150/150/122/150/300/150/60/110/230/460/180/170/151/15
Most frequent other events
Showing 10 of 396
Most frequent other events
EventStage 1 mUC Cohort: Atezo (Control)Stage 1 mUC Cohort: Atezo + EVStage 1 mUC Cohort: Atezo + Hu5F9-G4Stage 1 mUC Cohort: Atezo + NiraStage 1 mUC Cohort: Atezo + RO7122290Stage 1 Cohort 1 mUC Atezo+SGStage 1 mUC Cohort: Atezo + TiraStage 1 mUC Cohort: Atezo + TCZStage 1 MIBC Cohort 1: Atezo (Control)Stage 1 MIBC Cohort 1: Atezo + TiraStage 1 MIBC Cohort 2: Atezo (Control)Stage 1 MIBC Cohort 2: Atezo + TiraStage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control)Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + TiraStage 2 mUC Cohort: Atezo + EVStage 2 mUC Cohort: Atezo + SG
PruritusSkin and subcutaneous tissue disorders7/295/154/152/154/127/1510/303/151/69/114/2316/462/186/175/154/15
AnaemiaBlood and lymphatic system disorders6/296/158/157/151/1210/153/301/151/64/116/2316/4610/1810/174/157/15
AlopeciaSkin and subcutaneous tissue disorders0/292/150/150/150/126/150/300/152/60/110/232/461/181/179/156/15
NauseaGastrointestinal disorders1/294/152/154/151/127/1510/300/151/61/114/2311/469/1810/174/156/15
Decreased appetiteMetabolism and nutrition disorders7/298/154/154/154/125/157/301/151/61/113/2311/466/183/176/151/15
RashSkin and subcutaneous tissue disorders5/293/151/152/154/124/156/301/150/65/112/2317/463/186/178/150/15
FatigueGeneral disorders6/297/155/155/153/123/1514/302/152/62/118/2320/469/187/176/153/15
Blood creatinine increasedInvestigations6/292/153/154/151/123/154/302/153/62/113/239/465/183/172/151/15
Urinary tract infectionInfections and infestations5/292/156/151/151/123/157/303/151/63/117/2314/464/188/174/152/15
ConstipationGastrointestinal disorders3/295/152/153/150/126/158/305/150/61/116/2312/468/185/174/152/15

Baseline characteristics

All randomized population included all participants randomized to each treatment arm.

Age, Customized
Age, Customized(Participants)Stage 1 mUC Cohort: Atezo (Control)Stage 1 mUC Cohort: Atezo + EVStage 1 mUC Cohort: Atezo + Hu5F9-G4Stage 1 mUC Cohort: Atezo + NiraStage 1 mUC Cohort: Atezo + RO7122290Stage 1 mUC Cohort: Atezo + SGStage 1 mUC Cohort: Atezo + TiraStage 1 mUC Cohort: Atezo + TCZStage 1 MIBC Cohort 1: Atezo (Control)Stage 1 MIBC Cohort 1: Atezo + TiraStage 1 MIBC Cohort 2: Atezo (Control)Stage 1 MIBC Cohort 2: Atezo + TiraStage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control)Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + TiraStage 2 mUC Cohort: Atezo + EVStage 2 mUC Cohort: Atezo + SGTotal
Stage 1 — Adults (18-64 years)864646119225358——79
Stage 1 — From 65-84 years219128892064918441310——191
Stage 1 — 85 years and over10010000000000——2
Stage 2 — Adults (18-64 years)——————————————538
Stage 2 — From 65-84 years——————————————101121
Stage 2 — 85 years and over——————————————011
Sex: Female, Male
Sex: Female, Male(Participants)Stage 1 mUC Cohort: Atezo (Control)Stage 1 mUC Cohort: Atezo + EVStage 1 mUC Cohort: Atezo + Hu5F9-G4Stage 1 mUC Cohort: Atezo + NiraStage 1 mUC Cohort: Atezo + RO7122290Stage 1 mUC Cohort: Atezo + SGStage 1 mUC Cohort: Atezo + TiraStage 1 mUC Cohort: Atezo + TCZStage 1 MIBC Cohort 1: Atezo (Control)Stage 1 MIBC Cohort 1: Atezo + TiraStage 1 MIBC Cohort 2: Atezo (Control)Stage 1 MIBC Cohort 2: Atezo + TiraStage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control)Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + TiraStage 2 mUC Cohort: Atezo + EVStage 2 mUC Cohort: Atezo + SGTotal
Stage 1 — Female536243641251023——56
Stage 1 — Male2512101381225115918371615——216
Stage 2 — Female——————————————448
Stage 2 — Male——————————————111122
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Stage 1 mUC Cohort: Atezo (Control)Stage 1 mUC Cohort: Atezo + EVStage 1 mUC Cohort: Atezo + Hu5F9-G4Stage 1 mUC Cohort: Atezo + NiraStage 1 mUC Cohort: Atezo + RO7122290Stage 1 mUC Cohort: Atezo + SGStage 1 mUC Cohort: Atezo + TiraStage 1 mUC Cohort: Atezo + TCZStage 1 MIBC Cohort 1: Atezo (Control)Stage 1 MIBC Cohort 1: Atezo + TiraStage 1 MIBC Cohort 2: Atezo (Control)Stage 1 MIBC Cohort 2: Atezo + TiraStage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control)Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + TiraStage 2 mUC Cohort: Atezo + EVStage 2 mUC Cohort: Atezo + SGTotal
Stage 1 — Hispanic or Latino10001220200224——16
Stage 1 — Not Hispanic or Latino271511121012251441023441614——237
Stage 1 — Unknown or Not Reported20531141010100——19
Stage 2 — Hispanic or Latino——————————————000
Stage 2 — Not Hispanic or Latino——————————————141428
Stage 2 — Unknown or Not Reported——————————————112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Stage 1 mUC Cohort: Atezo (Control)Stage 1 mUC Cohort: Atezo + EVStage 1 mUC Cohort: Atezo + Hu5F9-G4Stage 1 mUC Cohort: Atezo + NiraStage 1 mUC Cohort: Atezo + RO7122290Stage 1 mUC Cohort: Atezo + SGStage 1 mUC Cohort: Atezo + TiraStage 1 mUC Cohort: Atezo + TCZStage 1 MIBC Cohort 1: Atezo (Control)Stage 1 MIBC Cohort 1: Atezo + TiraStage 1 MIBC Cohort 2: Atezo (Control)Stage 1 MIBC Cohort 2: Atezo + TiraStage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control)Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + TiraStage 2 mUC Cohort: Atezo + EVStage 2 mUC Cohort: Atezo + SGTotal
Stage 1 — American Indian or Alaska Native00000000000000——0
Stage 1 — Asian84522796100700——51
Stage 1 — Native Hawaiian or Other Pacific Islander00000000000010——1
Stage 1 — Black or African American00000000001200——3
Stage 1 — White20106108716851022361718——193
Stage 1 — More than one race00000000000000——0
Stage 1 — Unknown or Not Reported21532161010200——24
Stage 2 — American Indian or Alaska Native——————————————000
Stage 2 — Asian——————————————437
Stage 2 — Native Hawaiian or Other Pacific Islander——————————————000
Stage 2 — Black or African American——————————————000
Stage 2 — White——————————————101121
Stage 2 — More than one race——————————————000
Stage 2 — Unknown or Not Reported——————————————112
08

Study locations

33 sites
  • UCLA Department of Medicine
    Los Angeles, California 90024, United States
  • UCSF Comprehensive Cancer Ctr
    San Francisco, California 94115, United States
  • Stanford Cancer Center
    Stanford, California 94305-5820, United States
  • University of Kentucky Chandler Medical Center
    Lexington, Kentucky 40536, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40241, United States
  • Memorial Sloan-Kettering Cancer Center
    Commack, New York 11725, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106-1716, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030-4009, United States
  • Centre Francois Baclesse
    Caen, 14076, France
  • Centre Leon Berard
    Lyon, 69008, France
  • Institut régional du Cancer Montpellier
    Montpellier, 34298, France
  • Institut Claudius Regaud
    Toulouse, 31052, France
  • Attiko Hospital University of Athens
    Athens, 12462, Greece
  • Athens Medical Center
    Athens, 151 25, Greece
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea
  • Severance Hospital
    Seoul, 120-749, South Korea
  • Complejo Hospitalario Universitario de Santiago (CHUS)
    Santiago de Compostela, LA Coruna 15706, Spain
  • Clinica Universitaria de Navarra
    Pamplona, Navarre 31008, Spain
  • Vall d?Hebron Institute of Oncology (VHIO), Barcelona
    Barcelona, 08035, Spain
  • Hospital Clinic i Provincial
    Barcelona, 08036, Spain
  • Institut Catala d Oncologia Hospitalet
    Barcelona, 08908, Spain
  • Hospital Universitario Reina Sofia
    Córdoba, 14004, Spain
  • Hospital General Universitario Gregorio Mara
    Madrid, 28009, Spain
  • MD Anderson Cancer Center
    Madrid, 28033, Spain
  • Hospital Universitario Fundacion Jimenez Diaz.
    Madrid, 28040, Spain
  • Hospital Univ 12 de Octubre
    Madrid, 28041, Spain
  • START Madrid. Centro Integral Oncologico Clara Campal
    Madrid, 28050, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, 46010, Spain
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung City, 807, Taiwan
  • Royal Marsden NHS Foundation Trust
    Sutton, SM2 5PT, United Kingdom
09

References and documents

Publications

  • Drakaki A, Powles T, Bamias A, Martin-Liberal J, Shin SJ, Friedlander T, Tosi D, Park C, Gomez-Roca C, Joly Lobbedez F, Castellano D, Morales-Barrera R, Moreno-Candilejo I, Flechon A, Yuen K, Rishipathak D, DuPree K, Young F, Michielin F, Shemesh CS, Steinberg EE, Williams P, Lee JL. Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma). Clin Cancer Res. 2023 Nov 1;29(21):4373-4384. doi: 10.1158/1078-0432.CCR-23-0798. PubMed 37651261 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Oct 2025, 76 months.

Results were first posted in Aug 2026, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2019
First posted
Mar 11, 2019
StartActual
Jun 1, 2019
Primary completionActual
Oct 8, 2025
CompletionActual
Dec 22, 2025
Results first posted
Aug 3, 2026
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03869190
Lead sponsor
Hoffmann-La Roche
Collaborators
Gilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and Astellas
Responsible party
Sponsor
First posted
Mar 11, 2019
Start date
Jun 1, 2019
Primary completion
Oct 8, 2025
Completion
Dec 22, 2025
Results posted
Aug 3, 2026
Last update
Aug 3, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Enfortumab vedotin · Niraparib · Magrolimab · Tiragolumab · Sacituzumab govitecan · Tocilizumab · Cisplatin · Gemcitabine

Start the discussion